The suppression of normal acidity in the stomach is probably the basis for all the bad things that happen with PPI’s, so Voquenza would be expected to be an even worse agent if it is indeed so potent. The majority of individuals who have GERD don’t have excessive stomach acidity, and there are functional items, especially being ideal body weight, not eating a few hours before bed and for some having a little elevation of the head can help. Dietary changes, avoidance of ethanol. caffeine, chocolate, blueberries are common items of advice.
To the original question that started this quote 2 years ago, here is the best answer I’ve found:
To reduce the health risks associated with the use of proton pump inhibitors (PPIs), several strategies can be implemented. Firstly, it is crucial to ensure that PPIs are prescribed only when there is a clear and appropriate indication, such as GERD, erosive esophagitis, or Zollinger-Ellison syndrome. Regularly reviewing the necessity of ongoing PPI therapy can help minimize unnecessary long-term use 1.
De-prescribing is an important strategy for patients without a definitive indication for chronic PPI use. This involves either tapering the dose or discontinuing the medication abruptly, depending on the patient’s condition and risk factors 1. Patients should be informed about the possibility of transient upper gastrointestinal symptoms due to rebound acid hypersecretion after stopping PPIs 1.
For patients who require long-term PPI therapy, using the lowest effective dose for the shortest duration necessary can help mitigate risks. Monitoring for potential adverse effects, such as vitamin B12 deficiency, hypomagnesemia, and increased fracture risk, is recommended, especially in patients with prolonged use 3 5.
In patients with multimorbidity and polypharmacy, careful assessment of PPI use is essential to avoid potential drug interactions and adverse effects. This population is particularly vulnerable to the risks associated with long-term PPI use, such as increased hospital admissions 4.
Additionally, clinicians should be aware of the potential for PPIs to alter the gut microbiota, which can increase the risk of infections like Clostridium difficile and pneumonia 5 7. Educating patients about these risks and ensuring they understand the importance of adhering to prescribed doses can further reduce health risks.
In summary, reducing the health risks of PPIs involves appropriate prescribing, regular review of therapy necessity, dose minimization, monitoring for adverse effects, and patient education. These strategies can help balance the benefits of PPI therapy with the potential risks, ensuring safer use of these medications. (ASHP Drug Compendium [Pantoprazole; Acid Ulcer Dyspepsia])